Business
Safety Shot Releases Second Quarter 2024 Results and Corporate Highlights
- Q2 Revenues Increased 40%- Q2 Operating Expenses Decreased 17.7%- Recent Clinical Trial Confirms Dramatic Reduction of Blood Alcohol Content- Revolutionary
About this update from Bonk, Inc.
[{"type":"text","content":"- Q2 Revenues Increased 40%- Q2 Operating Expenses Decreased 17.7%- Recent Clinical Trial Confirms Dramatic Reduction of Blood Alcohol Content- Revolutionary Formula to be Soon Released in Convenient 4-ounce Bottles- Powdered Version of Alcohol-reducing Nutraceutical to be Released in Q4 JUPITER, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the Company) the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, has released its financial results for its second quarter ended June 30, 2024 as well as a corporate highlights for the quarter. \"We are very excited about our financial performance and our achievements for the second quarter of 2024. A dramatic increase in our revenues with a dramatic decrease in our operating expenses only showcases Safety Shot’s determination to bring value to stakeholders,” stated CEO Jarrett Boon. “We have exciting things expected in the next couple of quarters and believe they will serve as catalysts to further strengthen the company’s financial results going forward. As we continue to execute our business strategy, we remain focused on enhancing our growth potential. This is illustrated by the promising clinical results the company reported this month as well as new partnerships and new product lines the company will be launching in the near future.” Second Quarter 2024 Highlights: Company reports a 40% increase in sales in the second quarter compared to the first quarter.Company reports a 17.7% decrease in operating expenses in the second quarter compared to the first quarter, highlighting significant progress in Safety Shot’s financial health.Company reveals significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences (\"CAHS\"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content (\"BAC\"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC. Within 30 minutes of consuming Safety Shot, participants showed a 30%-50% faster rate of alcohol reduction compared to the placebo group. Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is now ...